Abstract
Introduction
The microRNA field has only existed for 7 years, yet it has become one of the hottest topics in biological sciences and there now well over 3000 microRNA publications (PubMed-June 2008 -microRNAs as diagnostic/prognostic bio-markers -microRNAs as non-invasive diagnostic tools • microRNAs as therapeutic agents realised until 7 years later when another worm microRNA, let-7 was discovered [3] . Unlike lin-4, the sequence of let-7 was found to be highly conserved in almost all organisms [4] . It was soon realised that similar sequences were scattered throughout eukaryotic genomes that were first called microRNAs in 2001 [5] . Since then, over 6000 microRNAs have been identified from a huge range of both prokaryotic and eukaryotic organisms [6] . There are currently over 600 human microRNA sequences annotated in the miRBase database (http://microrna.sanger.ac.uk/sequences/), although it is believed that the true figure is closer to one thousand [7, 8] . Despite the relatively small number of microRNAs, because a single microRNA can target several hundred genes, and conversely a single target gene can cooperatively bind multiple microRNAs [9] , it is currently believed that between 10% and 30% of all human genes are a target for microRNA regulation [10, 11] . microRNAs are expressed in a tissue-/cell-specific manner, some expressed ubiquitously whilst others appear to be restricted to single cell types [12] . [13] of mRNA. The majority of human microRNAs are encoded within introns, exgenically, within the exons of non-coding mRNAs, or within the 3'UTR sequence of mRNA [14] . With the exception of microRNAs encoded within Alu repeat sequences, which are transcribed by Pol-III [15] [16, 17] . Pri-microRNAs are cleaved by the microprocessor complex consisting of a nulease Drosha, and a co-factor, DGCR8 in human beings, Pasha in Drosophila [18] . The resulting [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [21] . The strand that becomes the active mature microRNA is dependent upon which has the lowest free energy 5' end, whilst the other strand is degraded by an unknown nuclease [22, 23] . The loaded miRISC is guided by the mature microRNA sequence to its cognate recognition sequence in the UTR of the target mRNA. Although repression of translation without mRNA degradation appears to be the modus operandi of animal microRNAs, the situation appears to be more complex than previously thought, as there is now compelling evidence that microRNAs also effect transcriptional levels through de-adenylation and/or degradation [24] and may even positively affect translation in some instances [25] . How translational repression occurs remains unclear. It has been suggested that mRNA bound to the microRNA-miRISC complex may be sequestered away from the translational machinery in P-bodies that additionally act in concert with enzymes to remove the 5'-cap hence preventing translation [26, 27] . Alternatively it has been suggested that microRNAs may prevent recognition of the 5'cap by translation factors [28] .
microRNA biosynthesis and function

Mature microRNAs are 19-24 nucleotide non-coding singlestranded RNA molecules which regulate the expression of target genes through perfect (in plants) or imperfect (in animals) binding to the 3'-UTR (un-translated region) and possibly 5'-UTR
Aberrant expression of microRNA is a common feature of cancer
There is now compelling evidence that dysfunctional expression of microRNAs is a common feature of malignancy [29] [31, 32] . Using array comparative genomic hybridization of 283 microRNA loci in solid tumours, a large proportion were found to be associated with DNA copy number alterations [33] . These data suggest that dysregulation of microRNA expression by genomic alterations is probably a widespread phenomenon in cancer.
Global effects on microRNA expression can be exerted through aberrant expression/activity of components of the microRNA biosynthetic machinery. For example, reduced levels of Dicer but not Drosha in lung cancer have been associated with poor prognostic outcome [34] . Dicer was also found to be down-regulated in B-cell lymphomas (Lawrie-unpublished data) . Conversely upregulation of Dicer has been reported in lung adenocarcinoma [35] and prostate adenocarcinoma [36] and Drosha levels in cervical squamous cell carcinoma are up-regulated [37] . When endogenous microRNA processing was silenced in both cell lines and mice, they displayed enhanced cellular transformation and tumourgenesis, giving a pathological significance to the downregulation of tumour suppressor microRNAs in cancer [38] .
More recently, it has been found that microRNA expression can be influenced by treatment with either de-methylating agents or histone modifying agents (reviewed by [39] [43] . [45] .
The role of miR-150 in lymphocyte maturation was explored further by Zhou et al. who observed that ectopic expression of this microRNA in haematopoietic stem cells transplanted into mice had no effect on T cells, macrophages or granulocytes but greatly impaired formation of mature B cells [44]. More detailed investigation revealed that overexpression of miR-150 reduced numbers through increased apoptotic rates in different developmental stages of B cells with the exception of pro-B cells suggesting that this microRNA inhibits the transition from pro-to pre-B cell. miR-150 was recently shown to control B-cell differentiation in vivo though specific targeting of c-Myb levels
Mir (including miR-155) , the majority (9/11) of which were upregulated. In contrast, plasma cell development was associated with the down-regulation of (10/11) of microRNAs [49] . [50] .
Three microRNAs implicated in both B-cell developmental stages (miR-17, miR-20b and miR-106a) form part of the miR-17-92 cluster leading to the proposition that this cluster played a role in normal B-cell development. Subsequently, this has been found that the miR-17-92 cluster is indeed essential for normal B-cell development as its deletion in a murine model resulted in increased levels of the pro-apoptotic protein Bim and inhibited B-cell development at the stage of pro-to pre-B-cell transition
In addition, to the role of specific microRNAs, the general necessity of microRNAs in lymphocyte development was investigated by selective deletion of Dicer in the thymus at both an early stage of T-cell development and at a much later stage [51, 52] . Surprisingly [56] , other reports using much larger patients cohorts did not find a correlation [61, 62] [64] . A follow-up study by the same authors extended the profiling studies to 94 CLL cases and defined a prognostically significant 13-microRNA signature [65] . [67] . [68] . Interestingly a similar finding was reported in cases of splenic marginal zone lymphoma (SMZL) [69] . [49] . As well as miR-155 this study found that miR-196a was up-regulated, a microRNA that was shown in another study to be up-regulated along with neighbouring homeobox gene HOXB9 in cHL cell lines as a result of constitutively active ERK5 pathway [72] . [74, 75] . microRNA profiling of five cell lines representing these molecular subtypes identified differentially expressed microRNAs [76] [79, 80] [81] , suggesting a profound role for microRNAs in the pathogenesis of this disease. [82] . [83] . Expression of these microRNAs in the BL cell line Raji inhibited growth, which was associated with ERK5 protein levels. [84] . In tumours containing this integration, the miR-106a cistron, as well as component mature microRNA sequences, was found to be overexpressed. Using the same technique, the same group reported that the miR-17-92 cluster was also a common integration site [85] . [86] [87] [88] . EBV-associated microRNAs were recently profiled in a peripheral T-cell lymphoma case, which were consistent with a type II latency infection [89] .
Fulci et al. used a combination of cloning and qRT-PCR technologies to profile 56 CLL patients [62]. They found that miR-21 and miR-155 were highly overexpressed in CLL compared to controls whilst miR-92 was down-regulated and miR-223, miR-29b and miR-29c were up-regulated in cases with IgVH mutations. Consistent with these findings high expression of miR-16, miR-21 and miR-150 were reported in 37 CLL cases by qRT-PCR [66]. Furthermore, in situ hybridization (ISH) was used to show that CLL proliferation centres were characterized by low miR-150 but high miR-155 expression. A cloning strategy was used by Marton et al. to clone pools of patients (n ϭ 3) with either mutated (M) or non-mutated (NM) IgVH from which they obtained 287 and 237 clones respectively of which 32 and 24 clones represented 13 previously annotated microRNAs as well as the identification of 5 novel microRNAs
A further indication of the role that microRNAs could play in the pathogenesis of CLL was provided by Pekarsky et al. who found that the TCL1 oncogene, previously shown to be linked with an aggressive CLL phenotype, was regulated by miR-29 and miR181b in vitro and that levels of these microRNAs inversely correlated with levels of TCL1 expression in clinical samples of CLL
Hodgkin's lymphoma (HL)
Hodgkin's lymphoma (HL) accounts for approximately 1% of cancers worldwide and is characterized by the presence of relatively few Hodgkin/Reed-Sternberg (HRS) tumour cells surrounded by a non-neoplastic cellular infiltrate. Navarro et al. investigated the microRNA profile of 49 classical HL (cHL) cases along with 10 reactive lymph nodes (RLN) by qRT-PCR [70]. They identified a 25-microRNA signature associated with disease and 36 microRNAs differentially expressed between two histological subtypes of cHL (nodular sclerosing and mixed cellularity). However, only a subset of these microRNAs were also expressed in cHL cell lines suggesting the remainder of microRNAs were associated with non-neoplastic cells. Of note miR-138 expression was associated with clinical stage in both training and validation sets and miR-21, miR-134 and miR-138 expression was visualized in HRS cells by ISH. Although this study did not identify miR-155 expression as being highly expressed in cHL cases, at odds with other publications [71], they did visualize miR-155 expression in HRS cells by ISH. Microarray analysis of four cHL cell lines identified seven differentially expressed microRNAs
Non-Hodgkin's lymphoma Diffuse large B-cell lymphoma (DLBCL) Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma accounting for nearly 40% of all lymphoid tumours [73]. Gene expression and immunohistochemical studies of this clinically heterogeneous disease have revealed the presence of at least two prognostically distinct subtypes of DLBCL; those with a good prognostic outcome that are germinal centre B cell-like (GCB) and those with a worse prognosis that are activated B cell-like (ABC)
and in PEL, KSHV-miR-K12-11 but not miR-155 is expressed. Both microRNAs were expressed in 293T cells, leading to the identification of 66 genes that were commonly down-regulated, 20 of which had 3'-UTR seed matches that were involved in cell signalling, cell division and T-cell activation. This suggests that the overexpression of KSHV-miR-K12-11 caused by KSHV infection in B cells mirrors the malignant phenotype of miR-155 overexpression (see below) in non-virally induced DLBCL.
Other non-Hodgkin's lymphoma Mantle cell lymphoma (MCL) accounts for about 6% of NHLs and is an aggressive disease of poor prognosis with a median survival of only 3 years. The majority of patients harbour a t(11;14) translocation that leads to truncation and overexpression of cyclin D1 (CCND1). Recently it has been found that the truncation of the CCDN1 gene in the t(11;14) translocation alters miR-16-1 binding sites and that miR-16-1 alters CCDN1 mRNA expression
Myeloma is a plasma cell neoplasm that is essentially incurable with a median survival of 3 years accounting for nearly 2% of all deaths from cancer and about 20% of deaths from haematological cancers. Using myeloma cell lines Löffler et al. found that miR-21 expression is controlled by an up-stream enhancer that binds Stat3 and that miR-21 expression by IL-6 induction was dependent on Stat3 and that ectopically expressing miR-21 without IL-6 reduced apoptosis
Several B-cell malignancies including CLL, DLBCL, BL and EBV-transformed lymphoblastoid cell lines were associated with the down-regulation of miR-143 and miR-145
microRNA expression in T-cell lymphoma
T cell and natural killer cell lymphoma account for about 15% of total lymphomas and represent a heterogeneous group of diseases that compared with their B-cell counterparts are little understood. The direct role of microRNAs in these lymphomas has not yet been studied; rather the little research that has been carried out suggests a role for microRNAs in these diseases. Recently the T lymphoma causing murine leukaemia virus (MLV), was used in a screen to identify common proviral integration sites and found a high density of integrations upstream of the miR-106a cistron
Additionally, microRNAs have been found to be encoded in the avian T-cell lymphoma-causing virus, Marek's disease virus (MDV)
Lymphoma-associated oncomirs (miR-155 and the miR-17-92 cluster)
The non-coding BIC locus was originally identified as a common retrovirus integration site for avian leukosis virus (ALV) that despite being poorly conserved between avian, mouse and human genomes, enhanced lymphogenesis in a mouse myc model [90, 91] . Commenting on the observation by van [103] . In addition, overexpression of miR-17-92 has been described as a common feature of solid tumours irrespective of 13q31 amplification status [104, 105] , and indeed loss-of-heterozygosity covering the 13q31 locus is frequently observed in these tumours [33] .
Similar to BIC [90, 91] [106] .
O'Donnell and colleagues found that the miR-17-92 cluster itself was up-regulated through direct c-myc binding [107] and it has been suggested that the two factors act synergistically in carcinogenesis [101] . They [30, 34, 65, 76, [110] [111] [112] [113] [114] . Specifically in haematological malignancies, a 13-microRNA prognostic signature was identified from a study of 94 CLL patients, which was associated with other prognostic markers including IgVH status and ZAP70 expression [65] . More recently, a 27-microRNA signature was identified that could distinguish ALL from AML with 97-99% accuracy [115] , whilst miR-181a expression was found to discriminate between AML M1/M2 and M3/M3 stages [116] . Additionally, the expression of miR-21 was found to be an independent indicator of overall survival in DLBCL patients [76] . With the advent of more standardised and widely available high throughput technologies to identify microRNAs, this list can only increase in the coming years.
MicroRNAs as non-invasive diagnostic tools
The search for non-invasive tools for the diagnosis and management of cancer has long been a goal of cancer research that has led to great interest in the field of circulating nucleic acids in plasma and serum [117] . Many studies have shown that specific cancer characteristics, both genetic and epigenetic, are detectable in the plasma and serum of cancer patients and may be useful as a tool for early detection, diagnosis and follow-up of cancer patients [117] . microRNAs due to their small size are relatively resistant to RNase degradation and unlike mRNA can be successfully recovered intact from archival formalin-fixed paraffin-embedded (FFPE) material [76, 118, 119] , suggesting they would be eminently suitable candidates for detection in biological fluids. We were able to show the presence of circulating microRNAs for the first time and found that tumour-associated microRNAs (miR-21, 155 and 210) were present at significantly higher levels in DLBCL patient sera (n ϭ 60) than in healthy controls (n ϭ 43) [120] . Furthermore, we found that expression levels of serum miR-21, like that of tumoural material [76] , were associated with relapse-free survival times for these patients. More recently, placental microRNAs have also been detected in maternal plasma [121] . These findings open a new diagnostic potential for microRNAs that will undoubtedly grow in the future.
microRNAs as therapeutic agents
The association between aberrant expression of microRNAs and malignancy is now so compelling that research is rapidly focusing on the therapeutic use of these molecules. As 
